Sign in

DEXCOM (DXCM)

DexCom, Inc. is a medical device company specializing in the design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes management. The company sells integrated CGM systems, including the Dexcom G6 and G7, as well as the Stelo sensor, which is the first over-the-counter glucose biosensor in the U.S. . DexCom generates revenue from disposable sensors and reusable hardware, such as transmitters and receivers, with sales influenced by factors like seasonality and insurance deductible resets . In 2023, the company reported a significant increase in revenue, reflecting strong demand for its products .

  1. Dexcom G6 and G7 Integrated CGM Systems - Provides continuous glucose monitoring for diabetes management, used by patients, caregivers, and clinicians worldwide.
  2. Stelo Sensor - Offers a 15-day glucose monitoring solution for people with Type 2 diabetes who do not use insulin, available over-the-counter in the U.S.
  3. Disposable Sensors - Supplies sensors that are used with CGM systems, contributing to recurring revenue through regular replacements.
  4. Reusable Hardware - Includes transmitters and receivers that work with CGM systems, providing essential components for continuous glucose monitoring.

You might also like

NamePositionExternal RolesShort Bio

Kevin R. Sayer

ExecutiveBoard

Chairperson of the Board, President, and CEO

None

Joined Dexcom in 2007; CEO since 2015; instrumental in advancing Dexcom's CGM technology and market leadership.

View Report →

Jacob S. Leach

Executive

Executive Vice President and COO

None

Joined Dexcom in 2004; oversees operations and has contributed to CGM technology development.

Jereme M. Sylvain

Executive

Executive Vice President and CFO

None

Joined Dexcom in 2018; CFO since 2021; oversees financial operations and compliance.

Matthew Dolan

Executive

Executive Vice President of Strategy, Corporate Development & Dexcom Labs

None

Joined Dexcom in 2015; leads corporate strategy, partnerships, and Dexcom Labs.

Michael J. Brown

Executive

Executive Vice President and Chief Legal Officer

Board Member of Riding on Insulin

Joined Dexcom in 2022; oversees all legal and intellectual property matters.

Sadie M. Stern

Executive

Executive Vice President and Chief Human Resources Officer

None

Joined Dexcom in 2020; leads human resources and organizational development.

Bridgette P. Heller

Board

Independent Director

Board Member at Aramark Corporation, Integral Ad Science, Novartis AG, and Newman’s Own

Joined Dexcom's Board in 2019; has extensive experience in consumer healthcare and business leadership.

Eric J. Topol, M.D.

Board

Independent Director

Director at Scripps Translational Science Institute; EVP at Scripps Research Institute; Digital Medical Advisor to Blue Cross Blue Shield Association

Joined Dexcom's Board in 2009; renowned physician and thought leader in digital healthcare.

Karen Dahut

Board

Independent Director

CEO of Google Public Sector; Board Member at National Air and Space Museum and EisnerAmper LLP

Joined Dexcom's Board in 2020; recognized for leadership in digital transformation and innovation.

Kyle Malady

Board

Independent Director

EVP and CEO of Verizon Business; Board Member at CTIA; Member of President's NSTAC

Joined Dexcom's Board in 2020; provides expertise in telecommunications and technology.

Mark G. Foletta

Board

Lead Independent Director

Board Member at AMN Healthcare Services, Inc. and Enanta Pharmaceuticals, Inc.

Joined Dexcom's Board in 2014; provides financial and audit expertise.

Nicholas Augustinos

Board

Independent Director

Board Member at Aver, Inc. and California Health Care Foundation

Joined Dexcom's Board in 2009; has extensive experience in healthcare technology and strategy.

Rimma Driscoll

Board

Independent Director

EVP at Zoetis Inc.; Board Member at Pumpkin Insurance

Joined Dexcom's Board in 2023; brings expertise in global strategy and business development.

Steven R. Altman

Board

Independent Director

Chairman of the Board at Prospector Capital Corporation

Joined Dexcom's Board in 2013; brings expertise in intellectual property and corporate strategy.

  1. Despite your efforts to stabilize relationships with DME partners and become more channel agnostic, you're still losing some share; what concrete steps are you taking to regain lost DME share, and is it realistic to expect a return to your prior standing with DMEs in the near future?

  2. With the U.S. CGM market growth appearing to slow to around 10% in Q3, how confident are you in achieving your 2025 revenue target of $4.6 billion, and what specific strategies do you have in place to drive growth in a potentially slowing market?

  3. You mentioned a six-point impact from rebate dynamics on growth in Q3 and are expecting less impact in Q4; how will ongoing rebate pressures affect your pricing strategy and margins moving into 2025, and what actions are you taking to mitigate their impact on profitability?

  4. Given the uncertainty around the FDA approval timing for the 15-day G7 product, how are you incorporating potential delays into your 2025 financial projections, and what contingency plans do you have if the approval or rollout takes longer than anticipated?

  5. While you've reported record new patient starts this quarter, you've acknowledged that sales force productivity is still about three months behind; how will this lag affect your ability to meet your projected sequential growth in Q4 and adhere to your long-term guidance, and what specific measures are in place to accelerate productivity gains?

Research analysts who have asked questions during DEXCOM earnings calls.

Danielle Antalffy

UBS Group AG

4 questions for DXCM

Also covers: ABT, ATRC, BAX +15 more

Issie Kirby

Redburn Atlantic

4 questions for DXCM

Also covers: ALC, COO, PODD +1 more

Jayson Bedford

Raymond James

4 questions for DXCM

Also covers: AXGN, IART, ICUI +7 more

Joanne Wuensch

Citigroup Inc.

4 questions for DXCM

Also covers: ABT, BAX, BDX +18 more

Marie Thibault

BTIG

4 questions for DXCM

Also covers: ABT, ARAY, ATRC +14 more

Travis Steed

Bank of America

4 questions for DXCM

Also covers: ABT, AXNX, BAX +15 more

Christopher Pasquale

Nephron Research

3 questions for DXCM

Also covers: ALC, AXGN, BSX +12 more

Jeffrey Johnson

Robert W. Baird & Co. Inc.

3 questions for DXCM

Also covers: ALC, ALGN, BBNX +11 more

Larry Biegelsen

Wells Fargo & Company

3 questions for DXCM

Also covers: ABT, ALC, AXNX +24 more

Matthew O'Brien

Piper Sandler & Co.

3 questions for DXCM

Also covers: APYX, ATEC, ATRC +18 more

Matthew Taylor

Jefferies

3 questions for DXCM

Also covers: ALUR, BDX, CQP +18 more

Michael Kratky

Leerink Partners

3 questions for DXCM

Also covers: AXGN, BBNX, INSP +6 more

Michael Polark

Wolfe Research

3 questions for DXCM

Also covers: BSX, EMBC, INSP +10 more

Robert Marcus

JPMorgan Chase & Co.

3 questions for DXCM

Also covers: ABT, BAX, BDX +21 more

Steven Lichtman

Oppenheimer & Co. Inc.

3 questions for DXCM

Also covers: ALC, ANGO, COO +11 more

William Plovanic

Canaccord Genuity

3 questions for DXCM

Also covers: ATRC, CBLL, CVRX +9 more

Joshua Jennings

TD Cowen

2 questions for DXCM

Also covers: ABT, ALUR, ATEC +20 more

Matthew Miksic

Barclays PLC

2 questions for DXCM

Also covers: ABT, ATEC, BAX +15 more

Shagun Singh Chadha

RBC Capital Markets

2 questions for DXCM

Also covers: AXNX, GMED, INSP +10 more

Anthony Petrone

Mizuho Group

1 question for DXCM

Also covers: ADMA, ALC, BSX +22 more

Bill Plovanic

Canaccord Genuity

1 question for DXCM

Also covers: AORT, CBLL, IRTC +6 more

Brandon Vazquez

William Blair & Company, L.L.C.

1 question for DXCM

Also covers: ALGN, CBLL, CVRX +16 more

Colin Clark

Stifel Financial Corp.

1 question for DXCM

Also covers: INGN

David Roman

Goldman Sachs Group Inc.

1 question for DXCM

Also covers: ABT, BAX, BDX +16 more

Kyle Rose

Piper Sandler

1 question for DXCM

Also covers: STIM

Lawrence Biegelsen

Wells Fargo

1 question for DXCM

Also covers: ABT, ALC, BAX +15 more

Margaret Kaczor Andrew

William Blair

1 question for DXCM

Also covers: RMD, STAA

Mathew Blackman

Stifel

1 question for DXCM

Also covers: AHCO, ATEC, BBNX +7 more

Matt O'Brien

Piper Sandler Companies

1 question for DXCM

Also covers: BBNX, BSX, GMED +6 more

Matt Taylor

Jefferies & Company Inc.

1 question for DXCM

Also covers: BIO, ESTA, EW +9 more

Mike Polark

Wolfe Research, LLC

1 question for DXCM

Also covers: BBNX, BSX, EMBC +6 more

Patrick Wood

Morgan Stanley

1 question for DXCM

Also covers: ALC, BDX, BLCO +16 more

Richard Newitter

Truist Securities

1 question for DXCM

Also covers: AXNX, GKOS, GMED +18 more

Robbie Marcus

JPMorgan Chase & Co.

1 question for DXCM

Also covers: ABT, BLCO, CNMD +2 more

Shagun Singh

RBC Capital Markets

1 question for DXCM

Also covers: GMED, INSP, JNJ +7 more

Steve Lichtman

Oppenheimer & Co. Inc.

1 question for DXCM

Also covers: ANGO, LPTX, MCUR +1 more
Program DetailsProgram 1
Approval DateJuly 25, 2024
End Date/DurationJune 30, 2025
Total additional amount$750.0 million
Remaining authorization amount$0
DetailsEnhance long-term value of share price; repurchases in open market or privately negotiated transactions
YearAmount Due [Billions]Debt TypeInterest Rate [%]% of Total Debt
20251.21 Senior Convertible Notes0.25 49.2% = (1.21 / 2.457.5) * 100
20281.25 Senior Convertible Notes0.375 50.8% = (1.25 / 2.457.5) * 100

Competitors mentioned in the company's latest 10K filing.

CompanyDescription

In selling our current CGM systems, we compete directly with the Diabetes Care division of this company; they manufacture and market products for the single-point finger stick device market. We have competed with them and their Libre family of CGM products for many years. They have received FDA clearance to integrate certain versions of their Libre sensors into automated insulin delivery systems and are pursuing such integrations with third-party insulin delivery devices.

This company's Diabetes Group markets and sells a standalone glucose monitoring product called Guardian Connect, both internationally and in the United States, and a disposable CGM system called Simplera in international markets. They have developed or are developing insulin pumps integrated with continuous glucose monitoring systems that provide, among other things, the ability to suspend insulin administration while the user’s glucose levels are low and to automate basal or bolus insulin dosing.

Roche Diabetes Care

This division of Roche Diagnostics manufactures and markets products for the single-point finger stick device market, competing directly with our current CGM systems.

LifeScan, Inc.

This privately-held company manufactures and markets products for the single-point finger stick device market, competing directly with our current CGM systems.

Ascensia Diabetes Care

This company manufactures and markets products for the single-point finger stick device market, competing directly with our current CGM systems.

NameStart DateEnd DateReason for Change
Ernst & Young LLP2000 PresentCurrent auditor

Notable M&A activity and strategic investments in the past 3 years.

CompanyYearDetails

Distributor in Australia and New Zealand

2022

Deal Details: Although the deal value and structure were not disclosed, the acquisition enabled Dexcom to expand into the Australia and New Zealand markets, driving international revenue growth. Notably, the non-CGM revenue from this acquisition was excluded from organic revenue calculations in financial reports.

Recent press releases and 8-K filings for DXCM.

Dexcom: North America precision nutrition market projected to grow at 15.3% CAGR
·$DXCM
  • The North America precision nutrition market is projected to grow at 15.3% CAGR (2025–2032), with the US market reaching USD 5.46 billion by 2032.
  • In 2024, the US and Canada held 81% and 10.3% of the regional market respectively.
  • Abbott, Dexcom, Nestle, and DSM are key players driving the integrated diagnostics and supplements ecosystem expansion.
  • The 2024 FDA approval of consumer glucose monitors from Abbott and Dexcom enabled real-time biomarker tracking, enhancing personalized nutrition solutions.
  • In Canada, Personalized Plans & Subscription Services are forecast to grow at 17.2% CAGR, while Consultation Services are expected to see 19.1% CAGR over 2025–2032.
5 days ago
Dexcom outlines US CGM market growth to $4.23 B by 2033
·$DXCM
  • The US continuous glucose monitoring market is projected to expand from US$ 2.05 billion in 2024 to US$ 4.23 billion by 2033, representing a CAGR of 8.36%.
  • Expansion is driven by rising diabetes prevalence (over 38 million Americans), factory-calibrated sensors, smartphone connectivity, and real-time alerts boosting usability.
  • Medicare, Medicaid, and commercial payers have broadened CGM reimbursement, while federal telehealth policies support remote diabetes management.
  • Key barriers include high upfront and recurring sensor costs and user compliance issues such as alarm fatigue and tech complexity.
  • Forecast analysis spans 10 leading states, notably California, Texas, New York, Florida, and Illinois.
6 days ago
Dexcom outlines CEO succession, growth strategy at Wells Fargo conference
·$DXCM
CEO Change
Guidance Update
Product Launch
  • Dexcom will install Jake Leach as CEO on January 1, 2026, with immediate focus on executing 2025 revenue and operating margin commitments and issuing a new long-range plan in early 2026.
  • Management projects strong double-digit growth into the foreseeable future, underpinned by expanded CGM coverage in non-insulin Type 2 diabetes, U.S. Stelo OTC CGM adoption, and international market expansion.
  • The product roadmap features imminent commercial launch of the 15-day G7 sensor, growth of the Stelo platform (>$100 million in first 12 months), and development of G8 multi-analyte wearable in a 4–4.5 year cycle.
  • Gross margin expansion is expected from 15-day sensor cost savings, achieving a $10 G7 sensor cost target, new Irish manufacturing capacity, and declining freight/write-off headwinds, setting up leverage into 2026.
Sep 3, 2025, 7:24 PM
Dexcom reports Q2 2025 results and CEO succession plan
·$DXCM
Earnings
Guidance Update
CEO Change
  • Dexcom delivered $1.16 billion in worldwide revenue in Q2 2025, up 15% year-over-year, with U.S. revenue of $841 million and international revenue of $316 million.
  • The company raised its full-year 2025 revenue guidance to €4.60–4.625 billion (14–15% growth) and reaffirmed non-GAAP gross margin of ~62%, operating margin of ~21% and adjusted EBITDA margin of ~30%.
  • Founder and CEO Kevin Sayer will hand over CEO responsibilities to President Jake Leach in 2026, following Leach’s promotion to president in May 2025.
  • Product innovation remains a focus: the Stello app has surpassed 400,000 downloads, Dexcom launched AI-based smart food logging and secured FDA clearance for a 15-day G7 sensor slated for H2 2025 rollout.
  • Supply chain improvements included record production months and expedited shipping routes, restoring channel inventories and rebuilding internal finished-goods stock.
Jul 31, 2025, 1:40 AM
Dexcom expands coverage of G7 CGM under Ontario Drug Benefit
·$DXCM
  • Dexcom G7 continuous glucose monitor is now covered under the Ontario Drug Benefit program for eligible insulin-using residents, including those aged 65+, youth 24 or under without private insurance, long-term care and special care home residents, community care recipients, Ontario Works/ODSP participants, and Trillium Drug Program enrollees
  • With this inclusion, Dexcom G7 becomes the most covered CGM on Ontario’s government-funded programs, also encompassed by the Assistive Devices Program and Non-Insured Health Benefits alongside most private insurance plans
  • 1.7 million Ontarians live with diabetes in 2024, many of whom require insulin, highlighting the impact of broader access to CGM technology
  • Dexcom G7 is clinically proven to lower A1C, reduce hyper- and hypoglycemia, increase time in range, and is the #1 preferred glucose sensor by Canadian endocrinologists
Jul 30, 2025, 12:00 PM
Dexcom projects digital diabetes management market to reach USD 26.29 billion by 2032
·$DXCM
  • The global digital diabetes management market was valued at USD 13.45 billion in 2024 and is projected to reach USD 26.29 billion by 2032, implying a 7.42% CAGR from 2025 to 2032.
  • Continuous Glucose Monitoring (CGM) systems held the largest product share at 39.29% in 2024, while wearables led device types and hospitals accounted for 39.9% of end-use.
  • North America captured approximately 38% of the market in 2024, with the U.S. representing nearly 40% of global market size due to strong CGM reimbursement and value-based care incentives.
  • Recent industry developments include FDA approval in April 2025 of a 15-day wear extension for Dexcom’s G7 CGM and Abbott’s June 2025 launch of the next-gen Libre 3 with 9% MARD.
Jul 11, 2025, 1:12 PM
[Dexcom Q1 2025 Results, Guidance, Product Launch, Share Buyback & Board Update]
·$DXCM
Earnings
Guidance Update
Product Launch
Share Buyback
Board Change
  • Dexcom reported Q1 2025 revenue of $1.036B with 14% organic growth over Q1 2024, including U.S. revenue of $751M (+15%) and robust international performance .
  • The quarter delivered GAAP operating income of $133.7M (12.9% margin) and non-GAAP gross profit of $596M (57.5% margin) .
  • Updated FY 2025 guidance projects $4.60B in revenue and anticipates non-GAAP gross profit margins of ~62% .
  • The Board approved a $750M share repurchase program, with Q1 closing at approximately $2.7B in cash, underscoring strong financial flexibility .
  • Post-quarter, Dexcom received FDA clearance for the 15 Day Dexcom G7 System (MARD of 8.0%), supporting a launch in 2H25 .
  • Karen Dahut resigned from the Board effective May 8, 2025, with the departure not linked to any disputes; the 8-K was signed by CFO Jereme M. Sylvain on May 2, 2025 .
May 2, 2025, 12:00 AM
Dexcom Engages New Auditor Following EY Dismissal
·$DXCM
Auditor Change
  • Dexcom dismissed Ernst & Young LLP as its independent registered public accounting firm effective March 21, 2025, although EY’s audit reports for fiscal years ended December 31, 2024 and 2023 were unqualified and without any adverse comments.
  • The Audit Committee engaged Deloitte & Touche LLP as the new auditor for the fiscal year ending December 31, 2025, marking a transition in the company’s auditing practices.
Mar 25, 2025, 12:00 AM